4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one

• ChemBase ID: 53267
• Molecular Formular: C24H23FN4O3
• Molecular Mass: 434.4628232
• Monoisotopic Mass: 434.17541884
• SMILES: C(c1n[nH]c(=O)c2ccccc12)c1ccc(c(c1)C(=O)N1CCN(CC1)C(=O)C1CC1)F
• Canonical SMILES: O=C(N1CCN(CC1)C(=O)c1cc(ccc1F)Cc1n[nH]c(=O)c2c1cccc2)C1CC1
• InChI: InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
• InChIKey: FDLYAMZZIXQODN-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one
• IUPAC Traditional name: olaparib; 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-2H-phthalazin-1-one
• Synonyms: 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1 -phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Olaparib; KU-0059436; KU0059436; AZD2281(Olaparib); Olaparib

Database IDs

• CAS Number: 763113-22-0
• MDL Number: MFCD13185161
• PubChem SID: 162058030
• PubChem CID: 23725625

CALCULATED PROPERTIES

• Acid pKa: 11.06253
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): 1.9638772
• LogD (pH = 7.4): 1.9637947
• Log P: 1.9638784
• Molar Refractivity: 117.5269 cm^3
• Polarizability: 43.458267 Å^3
• Polar Surface Area: 82.08 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO

Safety Information

• Storage Condition: -20°C
• Storage Warning: IRRITANT
• TSCA Listed: false

Pharmacology Properties

• Target: PARP

Product Information

• Purity: 95%; 95+%; 97%
• Salt Data: Free Base

DETAILS

Selleck Chemicals - S1060

Research Area

• Description: Cancer

Biological Activity

• Description: Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively.
• Targets:

  PARP1

  ;

  PARP2

• IC50:

  5 nM

  ;

  1 nM ^[1]

• In Vitro: Olaparib would act against BRCA1 or BRCA2 mutations. AZD2281 is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]
• In Vivo: Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]
• Clinical Trials: Combining with cediranib, Olaparib is currently in Phase I/II study for treatment of recurrent papillary-serous ovarian, fallopian tube or peritoneal cancer or treatment of recurrent triple-negative breast cancer.
• Features: Olaparib is one of the first PARP inhibitors.

Protocol

• Protocol: Kinase Assay ^[1]
• FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD^+ final assay concentration, and 0.075 μCi ^3H-NAD^+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
• In vitro isolated enzyme assay: PARP-2 activity inhibition uses a variation of the PARP-1 assay in which PARP-2 protein (recombinant) is bound down by a PARP-2 specific antibody in a 96-well white-walled plate. PARP-2 activity is measured following ^3H-NAD+ DNA additions. After washing, scintillant is added to measure ^3H-incorporated ribosylations. For tankyrase-1, a α-Screen assay is developed in which HIS-tagged recombinant TANK-1 protein is incubated with biotinylated NAD+in a 384-well ProxiPlate assay. Alpha beads are added to bind the HIS and biotin tags to create proximity signal, whereas the inhibition of TANK-1 activity is directly proportional to the loss of this signal.
• Protocol: Cell Assay ^[1]
• Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
• Concentrations: 1-300 nM
• Incubation Time: 7-14 days
• Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.
• Protocol: Animal Study ^[3]
• Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice.
• Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
• Doses: 50 mg/kg
• Administration: Administered via i.p. injection at 10 μL/g of body weight

References

• References: [1] Menear KA, et al. J Med Chem, 2008, 51(20), 6581-6591.
• References: [2] Evers B, et al, Clin Cancer Res, 2008, 14(12), 3916-3925.
• References: [3] Rottenberg S, et al, Proc Natl Acad Sci U S A, 2008, 105(44), 17079-17084.
• References: [4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

REFERENCES

• Menear KA, et al. J Med Chem, 2008, 51(20), 6581-6591.
• Evers B, et al, Clin Cancer Res, 2008, 14(12), 3916-3925.
• Rottenberg S, et al, Proc Natl Acad Sci U S A, 2008, 105(44), 17079-17084.
• Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.